UnitedHealth’s stock rebounds amid DOJ probe and leadership stock purchases, reflecting market dynamics in healthcare, regulatory challenges, and sector shifts.

TD Cowen lowers UnitedHealth stock rating and price target due to increased risk and regulatory issues in Medicare Advantage and Medicaid sectors, amid ongoing criminal investigation. Brokerages maintain an outperform stance with long-term valuation upside noted.

UnitedHealth Group faces a DOJ investigation for possible Medicare fraud, leading to its worst monthly stock slump and raising regulatory and market concerns in the U.S. health insurance sector.

UnitedHealth Group reports higher medical loss ratio and earnings challenges in Medicare Advantage, signaling a strategic shift amid rising care costs and regulatory scrutiny.

UnitedHealth Group stock falls sharply as CEO changes and 2025 guidance withdrawal increase uncertainty. Analysis of implications for the health insurance market.

UnitedHealth downgraded to Neutral by BofA after suspending 2025 guidance due to Medicare Advantage challenges. Analyst price targets and ratings vary amid uncertainty.

UnitedHealth Group faces a securities class action lawsuit after slashing 2025 earnings guidance and reporting Q1 losses, raising issues on Medicare Advantage utilization and corporate disclosures.

UnitedHealth Group allocated $1.7 million for executive security following the death of UnitedHealthcare CEO Brian Thompson. The high-profile incident highlights executive safety and corporate governance in the health insurance sector.

Discover why UnitedHealth Group's stock experienced its largest decline in over 20 years following Q1 earnings that fell short of Wall Street expectations. Learn more about the factors influencing its financial performance and future outlook.

An analysis shows Medicare Advantage plans earned $33 billion more than Traditional Medicare in 2021 through coding differences. UnitedHealth Group received the largest share.